P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength
ECCO'20 Vienna
2020
P364 New insights into the molecular mechanisms of thalidomide in paediatric inflammatory bowel disease patients
ECCO'20 Vienna
2020
P367 Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn’s disease patients
ECCO'20 Vienna
2020
P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice
ECCO'20 Vienna
2020
P369 Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre
ECCO'20 Vienna
2020
P370 Endoscopic balloon dilatation in paediatric stricturing Crohn’s disease: A retrospective collaborative study of the paediatric IBD Porto group of ESPGHAN
ECCO'20 Vienna
2020
P371 Self-medication with analgesics in ulcerative colitis: Results of a patient survey
ECCO'20 Vienna
2020
P373 Telemedicine and inflammatory bowel disease: Results of the IBD assistant pilot project
ECCO'20 Vienna
2020
P375 Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis
ECCO'20 Vienna
2020
P376 Real life health care utilisation in paediatric patients with inflammatory bowel disease in the era of biologics
ECCO'20 Vienna
2020
P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience
ECCO'20 Vienna
2020
P379 Surveillance with chromoendoscopy to detect new dysplasia in inflammatory bowel disease
ECCO'20 Vienna
2020